NCT04998201Phase 2Completed

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

Study sponsor: Arrowhead Pharmaceuticals

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-02-10Actual

Enrollment · participants353Actual

Source updated2026-04-14Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-02-24 · 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Percent Change ~~from~~ Baseline ~~in Fasting Triglycerides (TG)~~ at Week 24

+ After

Measure: Percent Change From Baseline at Week 24 in Fasting TG

Check registry source

Study details

Conditions studied

Mixed Dyslipidemia

Treatments or interventions studied

ARO-APOC3DrugAlso known as Plozasiran
PlaceboDrug

Primary outcomes · main study measures

measure: Percent Change From Baseline at Week 24 in Fasting TG; description: Least square (LS) mean and standard error (SE) were calculated using mixed model repeated measures (MMRM) which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.; timeFrame: Baseline, Week 24

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history